The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer

Denaro, Nerina; Eg, Russi; Colantonio, I.; Adamo,; Merlano, M.

doi:10.1159/000339542

Cited by 13 publications

(16 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite promising pre-clinical results with anti-angiogenic therapies that have engendered a number of clinical trials, so far no conclusive results have been reported on the value of anti-angiogenic therapy in HNSCC [92]. Investigation is under way to evaluate the efficacy of dual EGFR-VEGF inhibitors, with pre-clinical trials using head and neck xenografts demonstrating excellent responses [93].…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

show abstract

“…The combination markedly increases the antitumor efficacy [13,14]. In HNSCC EGFR variant III is associated with Cetuximab resistance and leads to auto-activation and up-regulated VEGF further augmenting this pathway [15].…”

Section: Results Of Preclinical Datamentioning

confidence: 99%

“…It is possible that a dual inhibition of EGFR and VEGFR may help to stop the proliferation pathway [15].…”

Section: Results Of Preclinical Datamentioning

confidence: 99%

“…Median overall survival was 4.2 months with 6-and 12-month overall survival rates of 34.7% and 11.6% respectively. Angiogenic inhibitors, such as squalamine, Cediranib, Axitinib, Dalantarcept, Semaxanib and Sunitinib have been evaluated without satisfactory results [15]. Cilengitide was added to standard first line CT-Erbitux without showing PFS benefit over standard PF-Cet [21].…”

Section: Results Of Antiangiogenic Therapy In Hncmentioning

confidence: 99%

See 1 more Smart Citation

Angiogenesis in Head and Neck Cancer

EG¹

2014

J Cancer Sci Ther

View full text Add to dashboard Cite

Locally advanced Head and Neck Squamous Cell Carcinoma (HNC) is a challenging disease for the lack of effective therapies even in the era of molecular medicine (the five-year survival does not exceed 40%). For patients with metastatic and recurrent HNC the standard treatment is the combination of Cetuximab/Platinum and Fluorouracil but median overall survival rate for this population remains lower than 11%. The main reasons of these disappointing outcomes include acquired drug resistance, anti Epidermal growth factors variants, epithelial to mesenchymal transition and tumor hypoxia.Angiogenesis plays a crucial role in HNSCC development and proliferation. Drugs may interfere with the angiogenic process via different mechanisms and there is a sound rationale for combining anti-angiogenic agents with chemotherapy or multiple anti-angiogenic strategies. Promising preclinical results with angiogenic inhibitors have engendered a number of trials, but until now there are not yet conclusive data on the value of anti-angiogenic therapy in HNC.

show abstract

“…The patient prognosis is influenced by the quality of pretherapeutic staging, which includes assessment of tumor spread, the extent of vascular infiltration, and the cervical nodal status [2,3]. In the era of targeted cancer therapy, tumor detection at an early stage and follow-up care in due time are integral parts of the treatment protocol [4,5,6]. …”

Section: Introductionmentioning

confidence: 99%

<sup>18</sup>F-Fluorodeoxyglucose Uptake Level-Based Lymph Node Staging in Oropharyngeal Squamous Cell Cancer - Role of Molecular Marker Expression on Diagnostic Outcome

et al. 2015

View full text Add to dashboard Cite

Background: A prospective study was performed to assess standard uptake value (SUV)-level based ¹⁸F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) lymph node staging in 33 patients with oropharyngeal squamous cell cancer (OSCC) out of a total of 99 patients with head-and-neck squamous cell cancer (HNSCC) and the role of nodal molecular marker expression in diagnostic outcome prediction. Methods: Preoperative nodal PET/CT staging in 123 lymph nodes was correlated with postoperative lymph node histology, which served as gold standard. Tissue samples were prepared for immunohistochemistry of the excised lymph nodes. Results: The negative and positive predictive values (NPV and PPV) of PET for correct lymph node assessment were 100% and 93%, respectively. There was a significant association between SUVmax and lymph node histology (p < 0.0001) and a significant linear correlation between SUVmax and nodal size (Pearson's correlation coefficient r = 0.61336, p < 0.0001). The molecular marker E-Cadherin was significantly overexpressed in lymph node metastases (p < 0.0001). Benign lymph nodes showed significant 2-fold Bcl2 overexpression (p < 0.0001). However, the molecular marker expression profiles were inhomogeneous and did not allow valuable diagnostic outcome prediction. Conclusions: SUV level-based ¹⁸F-FDG-PET/CT lymph node assessment in OSCC still has to be considered as the most established and reliable staging tool. Lymph node molecular marker expression profiles need to be investigated further as they currently do not sufficiently contribute to therapy decision-making.

show abstract

The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer

Cited by 13 publications

References 90 publications

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Angiogenesis in Head and Neck Cancer

<sup>18</sup>F-Fluorodeoxyglucose Uptake Level-Based Lymph Node Staging in Oropharyngeal Squamous Cell Cancer - Role of Molecular Marker Expression on Diagnostic Outcome

Contact Info

Product

Resources

About